Note 17. Earnings per share
|
|
|
|
|
|
|
|
|
|
|
For the six-month period ended June 30, |
|
|
|
2025 |
|
|
2026 |
|
|
|
|
|
|
|
|
Net loss attributable to shareholders of Cellectis ($ in thousands) |
|
|
(41,863 |
) |
|
|
(39,584 |
) |
Weighted average number of outstanding shares, used to calculate basic and diluted net result per share |
|
|
100,231,292 |
|
|
|
100,587,696 |
|
Basic / Diluted net loss per share attributable to shareholders of Cellectis |
|
|
|
|
|
|
Basic and diluted net loss per share attributable to shareholders of Cellectis ($ /share) |
|
|
(0.42 |
) |
|
|
(0.39 |
) |
|
|
|
|
|
|
|
|
|
|
|
For the three-month period ended June 30, |
|
|
|
2025 |
|
|
2026 |
|
|
|
|
|
|
|
|
Net loss attributable to shareholders of Cellectis ($ in thousands) |
|
|
(23,736 |
) |
|
|
(21,819 |
) |
Weighted average number of outstanding shares, used to calculate basic and diluted net result per share |
|
|
100,305,204 |
|
|
|
100,647,451 |
|
Basic / Diluted net loss per share attributable to shareholders of Cellectis |
|
|
|
|
|
|
Basic and diluted net loss per share attributable to shareholders of Cellectis ($ /share) |
|
|
(0.24 |
) |
|
|
(0.22 |
) |
For the three- and six-month periods ended June 30, 2026 and 2025, potentially dilutive securities were excluded from the calculation of diluted net loss per share as their effect would have been anti-dilutive. These securities consist of stock options and warrants granted to employees and directors (see Note 16), as well as outstanding warrants ("BSAs") granted to the EIB (see Note 12).
|